Articles tagged with Brain Cancer
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Researchers at McMaster University have identified a critical vulnerability in metastatic brain cancer that can be exploited with new drugs. By targeting an enzyme called IMPDH, they anticipate preventing brain metastasis from occurring. The study has shown promising results and could lead to an alternative treatment option for patients
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers have developed a novel platform for testing radiation therapy effects on brain cells, providing insights into how the brain reacts to cancer treatment. The study aims to improve treatment strategies by understanding the impact of radiation on neural circuits, ultimately leading to personalized care for patients.
A new study reveals that a third of glioma cells, a type of brain tumor, fire electrical impulses. These hybrid cells combine features of neurons and glia, challenging the long-held notion that only neurons generate electric signals in the brain.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers at Florida State University have shown potential of a new treatment for pediatric brain cancer by enhancing natural killer immune cells to improve their ability to attack the disease. The study, published in Bioactive Materials, provides a critical part in addressing a major clinical need for children with brain cancer.
A new study finds that combining an inhibitor of a metabolic pathway with chemotherapy could improve treatment outcomes in triple negative breast cancer brain metastases. Inhibiting fatty acid synthase, an enzyme critical for cancer cell survival, shows promise in improving chemotherapy efficacy.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Scientists have mapped over 5,000 genetic variants in the 'tumour protection' gene BAP1 that significantly increase cancer risk. These variants can be used to develop new treatments, including IGF-1 inhibitors, to slow down or prevent cancer progression.
Ternarx aims to unlock the potential of targeted protein degrader (TPD) technology to treat hard-to-treat cancers like neuroblastoma and prostate cancer. The company will initially focus on developing new treatments for these diseases using novel TPD technology.
A new surgical platform using mass spectrometry identifies key gene mutations in brain cancer, including IDH mutations, during surgery. This allows for rapid diagnosis, prognosis, and tumor resection to improve patient outcomes.
Researchers have developed an AI algorithm that can track protein clumping under the microscope in real-time, revolutionizing the study of neurodegenerative disorders. The tool helps identify key characteristics of clumped proteins, which can lead to new therapies.
Researchers at Ben-Gurion University have discovered a molecular mechanism that enables cancer cells to survive under glucose starvation. By targeting this pathway, they aim to develop a molecule that can block the survival of tumor cells while leaving healthy cells unaffected.
Researchers at Tampere University and Hospital discovered that aberrant DNA methylation contributes to the development of aggressive AT/RT brain tumors in young children. This finding paves the way for a deeper understanding of the disease and potential new treatments.
Researchers at Johns Hopkins Medicine have developed a novel approach to target group 3 medulloblastoma tumors in mice, reducing tumor growth by 40-50% and extending survival by up to 84 days. The therapy uses antisense oligonucleotides to block lnc-HLX-2-7 from binding to the HLX promoter region.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
A study of over 1.9 million US veterans found moderate to severe traumatic brain injuries associated with later brain cancer diagnoses, while mild TBI showed no link. The research highlights the need for further investigation into long-term health effects of TBI on war veterans.
Recent advances in permeating the brain-blood barrier hold promise for using radiopharmaceuticals to treat brain tumors. Theranostic approaches show encouraging preliminary results, particularly for meningiomas and pediatric brain tumors.
Researchers from Brigham and Women's Hospital and MIT unveiled a new microscopy technology called decrowding expansion pathology (dExPath) that provides novel insights into brain cancer development. The technology enables scientists to study neurological diseases at a never-before-achieved nanoscale level on conventional clinical samples.
Researchers have uncovered the molecular and ultrastructural features of BCAS1+ cells in diffuse gliomas, highlighting their proliferative capacity and distribution. The study provides a comprehensive characterization of the BCAS1+ cell population within diffuse gliomas, shedding light on its role in tumor malignancy.
Researchers have identified regional biological signatures in invasive brain tumor margins of high-grade glioma, which could lead to improved diagnosis, prognosis, and treatment. Advanced MRI techniques may help distinguish between the genetic and molecular alterations, providing insights into resistance to treatment.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
A team of researchers created a 3D bioprinted brain blood vessel model to investigate the impact of blood vessel curvature on metastatic cancer development. The model revealed that increased blood vessel curvature correlates with heightened cancer cell adherence and extravasation.
Researchers discovered that a little-understood synapse in the brain plays a pivotal role in producing myelin, the protective sheath around nerve cells. This finding could lead to new therapies for multiple sclerosis, neurodegenerative conditions and brain cancer.
Researchers studied cellular functions in medulloblastoma to understand its genetic causes and develop targeted therapies. The study identified essential microproteins that play a crucial role in the survival of cancer cells.
Researchers developed a novel platform to transport therapeutic antibodies across the blood-brain barrier using a biocompatible polymer. The method showed promising results in both in vitro and mouse-model experiments, suggesting enhanced brain delivery of cancer-fighting antibodies without inducing adverse effects.
Researchers at the University of Rochester Medical Center find that microglia can trigger cognitive deficits after radiation exposure, potentially targeting them for therapy development. Mice studies showed that blocking a specific pathway in microglia prevented cognitive decline, offering hope for improving patients' quality of life.
A new study found that perivascular fibroblasts support the creation of an immunosuppressive tumor microenvironment, allowing glioblastoma to evade the immune system. The fibroblasts may also promote stem-like cancer cells that rarely divide, leading to poor survival outcomes.
A systematic review of papers found abnormalities in brain cancer and potential treatment with licensed drugs. Genetic differences were discovered between smokers and non-smokers, suggesting personalized medicine approaches.
A Phase II clinical trial has shown a clear clinical benefit of combining Dabrafenib and Trametinib in treating BRAF mutated low-grade paediatric gliomas. The combination therapy improved overall response rate by over four-fold and increased median progression-free survival.
A $5 million NIH grant is expanding the University of Illinois Chicago's neurology tissue bank into a citywide effort to study epilepsy and brain cancer. The project will create a powerful new resource combining brain tissue data with clinical, functional, genetic, and 3D imaging information.
A pioneering collection of brain metastasis living samples has been established, enabling researchers to study the response to specific drugs and identify the best therapeutic options for each patient. The RENACER network connects hospitals and patients, facilitating the rapid sharing of research findings and clinical trial data.
Two parallel projects publish detailed cell atlases of the adult human brain and brain development, revealing over 3,000 cell types, including new insights into brain diseases and potential therapeutic targets. The freely available brain atlases will enable researchers to compare healthy brains with diseased ones.
Researchers classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describing its involvement in key canonical cancer signaling pathways. Methods to inhibit UGDH and its downstream products are also identified.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
Researchers unveil a groundbreaking MRI technology that non-invasively assesses brain iron homeostasis, shedding light on its role in normal brain function, aging, and disease. The technology offers sensitivity to changes in iron mobilization capacity and can differentiate between tumor tissue and healthy tissue.
Researchers at The Hospital for Sick Children have discovered a designer peptide that targets a previously unknown protein-protein interaction in glioblastoma cells, resulting in the death of tumor cells across all subtypes. The treatment approach showed robust therapeutic efficacy and no side effects in preclinical models.
A team of clinical psychologists at VCU Massey Cancer Center is implementing a virtual telehealth therapeutic intervention program to treat insomnia among military members, veterans and their family members with brain cancer. Cognitive Behavioral Therapy for Insomnia (CBT-I) will be used as the front-line treatment option.
Researchers developed a molecular test to identify brain tumors by analyzing genetic material in cerebrospinal fluid. The Real-CSF test correctly identified 67% of cancerous and 96% of noncancerous brain lesions, outperforming standard cytology methods.
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer. The treatment improved survival...
Patients with cancer who live in rural Pennsylvania counties are more likely to receive complex surgeries at high-volume hospitals due to their perceived better outcomes. However, for less complex surgeries, rural patients are less likely to opt for high-volume hospitals despite potential benefits from centralization.
Researchers find immunotherapy treatment anti-CTLA-4 leads to greater survival in mice with glioblastoma and discover new way cells kill cancer by triggering microglia, specialized immune cells in the brain. This breakthrough could lead to more effective treatments for human brain cancer.
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
A study by Dana-Farber Cancer Institute researchers found that gliomas can arise from epigenetic changes, which affect gene activity without altering DNA sequence. The findings pinpoint two genes, an oncogene and a tumor suppressor, whose activities are epigenetically altered in human gliomas.
Researchers at Mass General Cancer Center treated 16 patients with a BRAF/MEK inhibitor, resulting in a 91% reduction in tumor size and complete response in all patients who received one or more cycles of therapy. The treatment showed unprecedented success in targeting brain tumors using precision medicine approaches.
Researchers have developed a technology to capture and release cell-free DNA from urine using nanowire surfaces, successfully detecting IDH1 mutation in glioma patients. This method opens possibilities for the detection of other tumor mutations and could revolutionize cancer diagnosis.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A new evidence-based framework proposes integrating palliative care into neurology teams to address the total pain of neurologic illness, including psychological, social, and spiritual distress. This approach aims to screen for and prevent suffering by incorporating a palliative care model from day one.
Researchers have made a significant finding in detecting brain tumors by exploiting folate receptors. Folate receptor expression is significantly higher in glioma tissue compared to adjacent healthy brain tissue, presenting a promising target for future treatments.
Researchers have developed a biodegradable ultrasound device that can open the blood-brain barrier, allowing chemotherapy to penetrate and kill brain cancer cells. The device is as powerful as traditional ceramic-based devices and has shown promising results in animal trials.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
Researchers found that rare brain tumor patients struggle to access therapy and experience devastating psychological impact after diagnosis. The study calls for improved mental health services and specialized support for these patients.
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
A phase 2 trial found that immune checkpoint inhibitor pembrolizumab had a durable antitumor effect in 24 of 57 patients with metastatic brain cancer. The study achieved its primary endpoint, with median overall survival of 8 months and seven patients surviving longer than two years.
Researchers have created an open-source, reproducible analysis platform for pediatric brain tumors, providing a cloud-based resource for comprehensive data on the disease. The platform contains genomic and clinical data from over 1,000 pediatric brain tumors and 22 patient-derived cell lines.
Researchers presented findings on pembrolizumab for brain metastases, virtual mind-body interventions for post-treatment survival, and dynamic HER2-low status in triple negative breast cancer. The studies aim to improve treatments and outcomes for patients with cancer.
A recent meta-analysis shows that amino acid PET can accurately differentiate between recurrent brain metastases and treatment-related changes. This technology has the potential to reduce unnecessary invasive procedures and overtreatment in patients with cancer.